Last reviewed · How we verify
NCT06248606
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Recruiting now
Phase 2
Last updated 8 April 2026
What this trial tests
Phase 2 trial testing Adagrasib in Non Small Cell Lung Cancer in 30 participants. Currently enrolling.
Timeline
6 August 2024
Primary endpoint
25 February 2027
25 February 2027
25 February 2028
Quick facts
| Lead sponsor | Ryan Gentzler, MD |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 6 August 2024 |
| Primary completion | 25 February 2027 |
| Estimated completion | 25 February 2028 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Adagrasib (ADAGRASIB) — full drug profile →
- Stereotactic Radiosurgery
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
- NSCLC — all drugs for NSCLC →
- KRAS G12C — all drugs for KRAS G12C →
Sponsor
Ryan Gentzler, MD
Who can join
18 and older, any sex, with Non Small Cell Lung Cancer or NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. · · 2024 · cited 43× · PMID 39164274 · DOI 10.1038/s41392-024-01907-z -
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.
Tenekeci AK, Unal AA, Ceylan F, Nahit Sendur MA. · · 2024 · cited 6× · PMID 39360933 · DOI 10.1080/14796694.2024.2407280 -
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.
Frisch A, Martin E, Kim SY, Riess JW, et al · · 2025 · cited 4× · PMID 40586765 · DOI 10.1093/oncolo/oyaf153 -
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer.
Dekker SE, Deng L. · · 2024 · cited 4× · PMID 39594840 · DOI 10.3390/cancers16223885 -
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu S, Ma J, Cai C, Tan J, et al · · 2025 · cited 3× · PMID 40611261 · DOI 10.1186/s13046-025-03444-1 -
The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?
de Souza Barbosa I, Pilotto Heming C, Moura Neto V, Aran V. · · 2025 · cited 2× · PMID 40362343 · DOI 10.3390/ijms26094104 -
Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.
Chen H, Li S, Yang Q, Zhou F. · · 2026 · PMID 42109678 · DOI 10.3389/fonc.2026.1821752 -
Therapeutic advances with KRAS<sup>G12C</sup> inhibitors and combination strategies in non-small cell lung cancer brain metastases.
Bhattacharya D, Roman B, Reddy S. · · 2026 · PMID 41663526 · DOI 10.1038/s41417-026-01003-0
Verify or expand the search:
- PubMed search for NCT06248606
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adagrasib
Trials testing the same drug.
- NCT07382726 — Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial · Phase 1 · not yet recruiting
- NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT06875310 — A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan · Phase 3 · recruiting
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06248606 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ryan Gentzler, MD
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06248606.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing